Effect of Yugengtongyu Granules in Patients with Stable Coronary Artery Disease on Reducing Adverse Cardiovascular Events: A Double-Blind Controlled Trial

医学 双盲 内科学 冠状动脉疾病 心脏病学 不利影响 安慰剂 疾病 替代医学 病理
作者
Dayang Wang,Chunyan Li,Xiaoqing Xu,Hui Xu,Congcong Guo,Jinping Wang,Jingyin Guo,Li Huang
出处
期刊:Journal of Alternative and Complementary Medicine [Mary Ann Liebert, Inc.]
卷期号:27 (2): 142-149 被引量:8
标识
DOI:10.1089/acm.2020.0361
摘要

Objectives: To evaluate the effect of Yugengtongyu granules on reducing the incidence of adverse cardiovascular events and improving quality of life (QOL) in patients with stable coronary artery disease (SCAD). Methods: A double-blind randomized controlled trial was conducted among SCAD population. One hundred fourteen patients were randomly assigned to experimental group (n = 57) and control group (n = 57) following randomized block design. Combined with the basis of standard treatment of SCAD, the experimental group and control group received Yugengtongyu granules or placebo, respectively, twice daily for 6 months and were followed for another 1 year (18 months in total from enrollment). Major outcomes (any occurrence of cardiovascular death, nonfatal myocardial infarction, or coronary revascularization), minor outcomes (any occurrence of all-cause death, ischemic stroke, readmission due to unstable angina, heart failure, or malignant arrhythmia), and composite outcomes (union of major and minor outcomes) were used to evaluate prognosis; Seattle Angina Questionnaire (SAQ) was applied to evaluate QOL, and levels of low density lipoprotein-cholesterol (LDL-C) and high sensitive C reacting protein (HS-CRP) in serum were tested. Results: The incidence of composite outcomes in the experimental group was significantly lower than that in the control group (3 [5.2%] vs. 11 [19.2%], hazard ratio: 0.273, 95% confidence interval: 0.080–0.926, p = 0.022); major outcomes, minor outcomes, and independent events such as nonfatal myocardial infarction showed lowering trend in experimental group. Experimental group scored significantly higher than control group in four dimensions of SAQ: physical limitation, angina frequency, treatment satisfaction, and disease perception at the third- and sixth-month follow-up; there was no significant difference in serum level of LDL or HS-CRP at all scheduled timepoints. Conclusion: The addition of Yugengtongyu granules based on current standard treatment reduced the incidence of composite outcomes and improved QOL in patients with SCAD. The trial was registered in the Chinese Clinical Trial Registry (ChiCTR-TRC-13004370).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6.4的应助被nwy采纳,获得10
刚刚
十二完成签到,获得积分0
1秒前
youkang完成签到,获得积分10
1秒前
芋泥啵啵发布了新的文献求助10
1秒前
jiacooo发布了新的文献求助10
1秒前
勿忘发布了新的文献求助10
2秒前
星辰大海的应助被cc采纳,获得20
2秒前
Arina发布了新的文献求助10
2秒前
领导范儿的应助被壮观雁易采纳,获得10
2秒前
3秒前
华仔的应助被科研通管家采纳,获得10
3秒前
香蕉觅云的应助被科研通管家采纳,获得10
3秒前
大模型的应助被科研通管家采纳,获得10
3秒前
3秒前
情怀的应助被科研通管家采纳,获得10
3秒前
充电宝的应助被科研通管家采纳,获得10
3秒前
爆米花的应助被科研通管家采纳,获得10
3秒前
搜集达人的应助被科研通管家采纳,获得10
4秒前
酷波er的应助被逢考必过采纳,获得10
4秒前
今后的应助被科研通管家采纳,获得30
4秒前
bkagyin的应助被科研通管家采纳,获得10
4秒前
无花果的应助被科研通管家采纳,获得10
4秒前
无花果的应助被科研通管家采纳,获得10
4秒前
Lucas的应助被Lu采纳,获得10
4秒前
我是老大的应助被科研通管家采纳,获得10
4秒前
无情愫的应助被科研通管家采纳,获得10
4秒前
大个的应助被科研通管家采纳,获得10
5秒前
汤包发布了新的文献求助10
5秒前
科目三的应助被科研通管家采纳,获得30
5秒前
风吹麦浪的应助被科研通管家采纳,获得10
5秒前
Jun的应助被科研通管家采纳,获得10
5秒前
秋风的应助被科研通管家采纳,获得20
5秒前
Jun的应助被科研通管家采纳,获得30
5秒前
充电宝的应助被科研通管家采纳,获得10
5秒前
科目三的应助被科研通管家采纳,获得10
5秒前
drizzle发布了新的文献求助10
5秒前
6秒前
天天快乐的应助被科研通管家采纳,获得10
6秒前
赘婿的应助被科研通管家采纳,获得10
6秒前
ding的应助被科研通管家采纳,获得10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184267
求助须知:如何正确求助?哪些是违规求助? 9573323
关于积分的说明 21830790
捐赠科研通 7781314
什么是DOI,文献DOI怎么找? 3434307
关于科研通互助平台的介绍 2558389
邀请新用户注册赠送积分活动 2480817